ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 620,00
0,21%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Orchard Therapeutics PLC (ORTX)

  7. Orchard Therapeutics PLC (ORTX) Actualités

ORTX Orchard Therapeutics PLC

16,70
0,00 (0,00%)
31 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Orchard Therapeutics PLC ORTX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 16,70 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
16,70 16,70
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
07/5/202413:00GLOBEOrchard Therapeutics Announces Multiple Presentations at..
03/5/202413:00GLOBEOrchard Therapeutics Co-founder and Chief Executive Officer..
20/3/202412:00GLOBEOrchard Therapeutics Outlines U.S. Launch Plans for..
18/3/202420:41GLOBEOrchard Therapeutics Receives FDA Approval of Lenmeldy™..
15/2/202403:05EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05/2/202420:39EDGAR2Form 15-12G - Securities registration termination [Section..
05/2/202413:00GLOBEOrchard Therapeutics Announces First Patient Randomized in..
02/2/202413:00GLOBEOrchard Therapeutics Announces Multiple Presentations at the..
31/1/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
25/1/202413:00GLOBEOrchard Therapeutics Announces Agreement with the Beneluxa..
24/1/202423:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202423:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202423:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202422:41EDGAR2Form S-8 POS - Securities to be offered to employees in..
24/1/202422:28EDGAR2Form POS AM - Post-Effective amendments for registration..
24/1/202422:17EDGAR2Form 8-K - Current report
24/1/202411:00GLOBEKyowa Kirin successfully completes acquisition of Orchard..
22/1/202422:10EDGAR2Form 8-K - Current report
19/12/202322:49EDGAR2Form 8-K - Current report
11/12/202313:00GLOBEOrchard Therapeutics Receives Swissmedic Approval for..
08/12/202322:39EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
08/12/202322:37EDGAR2Form 8-K - Current report
30/11/202322:13EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
30/11/202322:06EDGAR2Form 8-K - Current report
30/11/202313:00GLOBEOrchard Therapeutics Receives U.S. FDA Fast Track..
21/11/202313:53EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
21/11/202313:51EDGAR2Form 8-K - Current report
16/11/202322:45EDGAR2Form DEFM14A - Definitive proxy statement relating to merger..
13/11/202313:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202313:05EDGAR2Form 8-K - Current report
13/11/202313:00GLOBEOrchard Therapeutics Reports Third Quarter 2023 Financial..
03/11/202322:11EDGAR2Form PREM14A - Preliminary proxy statements relating to..
26/10/202322:35EDGAR2Form 8-K - Current report
26/10/202313:00GLOBEOrchard Therapeutics Announces Presentation of Additional..
24/10/202313:00GLOBEOrchard Therapeutics Announces Multiple Presentations at..
17/10/202322:32EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
05/10/202323:26EDGAR2Form DEFA14C - Additional information statement materials,..
05/10/202322:48EDGAR2Form DEFA14C - Additional information statement materials,..
05/10/202322:45EDGAR2Form DEFA14C - Additional information statement materials,..
05/10/202322:43EDGAR2Form DEFA14C - Additional information statement materials,..
05/10/202322:40EDGAR2Form DEFA14C - Additional information statement materials,..
05/10/202315:07EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
05/10/202315:05EDGAR2Form 8-K - Current report
05/10/202313:19IHMARKETNEWSThursday’s Wall Street Highlights: Orchard Therapeutics,..
05/10/202309:35GLOBEKyowa Kirin to Acquire Orchard Therapeutics
18/9/202313:07EDGAR2Form 8-K - Current report
18/9/202313:00GLOBEOrchard Therapeutics Announces Acceptance of Biologics..
31/8/202313:00GLOBEOrchard Therapeutics Announces Presentation of Data..
21/8/202322:32EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
10/8/202323:04EDGAR2Form S-8 - Securities to be offered to employees in employee..

Dernières Valeurs Consultées

NASDAQ
ORTX
Orchard Therapeutics
BIT
UB5UK4
Unicredit Bank
BIT
UC7T6K
Unicredit Bank
EU
R441S
R441S
LSE
BW95
Barclays Uk.30
BIT
INFL1
UBS ETF BBG Barc Euro In...
BIT
UC41KM
Unicredit Bank
BIT
I06597
Intesa Sanpaolo
USOTC
CHBAF
Chiba Bank (PK)
LSE
FC67
Nat Gas Trns 35
BIT
UC4PZ7
Unicredit Bank
USOTC
ELEZY
Endesa (PK)
EU
SGE2D
Euronext G EDF 151121 De...
BIT
UC79X8
Unicredit Bank
ASX
TLSLOP
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés